Search

Chronic obstructive pulmonary disease (COPD) is a chronic lung disease resulting from dynamic, cumulative gene-environment interactions that cause lung tissue injury, alteration of its normal function, and acceleration of cellular senescence. Long noncoding RNAs (lncRNAs) function as critical epigenetic regulators of various aspects of cellular senescence. The objective of the present study is to identify the association between polymorphic variants of H19 (rs3741219), MEG3 (rs7158663), MALAT1 (rs619586), LINC00305 (rs2850711), LINC00261 (rs6048205), CDKN2B-AS1 (rs4977574), and LINC02227 (rs2149954) lncRNAs genes with COPD. DNA samples from COPD patients (N = 703) and healthy individuals (N = 655) were studied in this study and polymorphic loci were analyzed by real-time PCR. Association with COPD was established with H19 (rs3741219), MEG3 (rs7158663), LINC02227 (rs2149954), MALAT1 (rs619586) and CDKN2B-AS1 (rs4977574). Polygenic analysis has made it possible to identify informative gene–gene combinations that include polymorphic variants of the studied lncRNAs genes and genes encoding molecules of signaling cascades associated with cellular senescence and apoptosis. Multiple regression and ROC analysis revealed a COPD risk predictive model, which included gene–gene combinations of lncRNAs genes and smoking index (P = 4.01 × 10–48, AUC = 0.87). [ABSTRACT FROM AUTHOR]

Chronic obstructive pulmonary disease is now one of the most common noncommunicable diseases and the main causes of morbidity, disability and mortality in the world. In recent years, new approaches to epidemiology, diagnosis, classification (categorization), evaluation of phenotypes, as well as characterization and assessment of the severity of сhronic obstructive pulmonary disease exacerbations have emerged. Modern approaches to starting and subsequent drug therapy have changed significantly. This is largely due to the results of recently conducted major clinical trials, demonstrated high efficacy of triple fixed combinations, including inhaled glucocorticosteroids, long-acting beta-agonists and long-acting anticholinergic drugs. The use of non-medication methods (smoking cessation, physical activity and respiratory rehabilitation) and modern approaches to the treatment of respiratory failure and antibiotic therapy remain important. In terms of their significance, all these updates have a significant impact on real clinical practice and can be considered as a novel paradigm of the approaches to the diagnosis and management of this disease.

Chronic obstructive pulmonary disease is now one of the most common noncommunicable diseases and the main causes of morbidity, disability and mortality in the world. In recent years, new approaches to epidemiology, diagnosis, classification (categorization), evaluation of phenotypes, as well as characterization and assessment of the severity of сhronic obstructive pulmonary disease exacerbations have emerged. Modern approaches to starting and subsequent drug therapy have changed significantly. This is largely due to the results of recently conducted major clinical trials, demonstrated high efficacy of triple fixed combinations, including inhaled glucocorticosteroids, long-acting beta-agonists and long-acting anticholinergic drugs. The use of non-medication methods (smoking cessation, physical activity and respiratory rehabilitation) and modern approaches to the treatment of respiratory failure and antibiotic therapy remain important. In terms of their significance, all these updates have a significant impact on real clinical practice and can be considered as a novel paradigm of the approaches to the diagnosis and management of this disease.